A new study conducted in France has found that nirsevimab, a monoclonal antibody treatment, was associated with significantly lower rates of respiratory syncytial virus (RSV) hospitalizations and severe outcomes in newborns compared to maternal vaccination using the RSV prefusion F protein (RSVpreF) vaccine. The findings provide new clinical data that could influence how health systems approach RSV prevention strategies in neonates. Researchers analyzed population-level data to assess the comparative effectiveness of both preventive interventions during the RSV season.
According to the study, infants who received nirsevimab faced a lower risk of RSV-related hospitalization than those whose mothers received the RSVpreF vaccine during pregnancy. The data indicated measurable differences in severe neonatal outcomes between the two groups, with nirsevimab-treated newborns faring better across multiple clinical metrics. The research adds to a growing body of evidence supporting the use of monoclonal antibody therapies as a frontline defense against RSV in vulnerable newborn populations.
RSV is one of the leading causes of respiratory illness and hospitalization in infants and young children worldwide, making effective prevention strategies a significant public health priority. Nirsevimab, marketed under the brand name Beyfortus, was approved in recent years as a preventive option for newborns and infants entering their first RSV season. Maternal vaccination with RSVpreF, sold as Abrysvo, has also been authorized as an alternative strategy, allowing immunity to be passed from mother to child before birth.
The French study is particularly significant because it offers a direct, real-world comparison between the two prevention approaches rather than measuring each against a placebo or control group. Health authorities and clinicians have been seeking this type of comparative data to better guide clinical decision-making and public health policy. France has been among the countries that moved swiftly to incorporate nirsevimab into its national immunization recommendations following the drug's regulatory approval.
Experts note that the findings do not necessarily render maternal vaccination ineffective, but suggest that direct immunization of newborns with nirsevimab may offer stronger protection in the critical early weeks of life. Both approaches carry distinct logistical and clinical considerations, including timing of administration, cost, and access. Further studies across different populations and geographic regions will likely be needed before global health agencies revise formal guidance based on these comparative outcomes.
